Is continuous dopaminergic delivery still a major goal to be achieved in the treatment of Parkinson's disease? [PDF]
J Parkinsons DisDi Lazzaro G +4 more
europepmc +1 more source
Cardiovascular pharmacology of dopaminergic agents in humans: a review. [PDF]
Clin Auton ResPalma JA, Gomez Casanovas JG.
europepmc +1 more source
Extra-helical allosteric binding site of apomorphine in ADGRG6. [PDF]
Cell DiscovQiu N +9 more
europepmc +1 more source
Nationwide analysis of real-world access to and use of device-aided therapies in Parkinson's disease: insights from the French National Healthcare Data System (2015-2021). [PDF]
BMJ Neurol OpenAuffret M, Nowak E, Vérin M, Kerbrat S.
europepmc +1 more source
Reduced DJ-1/Nrf2/HO-1 antioxidant signalling is associated with type 2 diabetes-related aggravation of neurodegeneration in a mouse model of Parkinson's disease. [PDF]
IBRO Neurosci RepXu H +8 more
europepmc +1 more source
Recent Developments in the Drug Treatment of Parkinson's Disease. [PDF]
DrugsLeiter S, Mahlknecht P, Poewe W.
europepmc +1 more source
Mitochondrial DNA Damage in Substantia Nigra Pars Compacta Astrocytes Exacerbates Dopaminergic Neuron Loss in a 6-Hydroxydopamine Mouse Model of Parkinsonism. [PDF]
Cell Mol NeurobiolAyala DA +9 more
europepmc +1 more source
Biochemical and nutritional changes during continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: findings from an observational cohort. [PDF]
Ther Adv Neurol DisordPhokaewvarangkul O +3 more
europepmc +1 more source
Structure-Affinity Relationship Optimization of SYA16263 Yields New Ligands with Improved Receptor Affinity and Antipsychotic-Like Properties. [PDF]
ACS OmegaGonela UM +9 more
europepmc +1 more source